AR072934A1 - Moleculas aglutinantes de nogo-a y uso farmaceutico de las mismas - Google Patents
Moleculas aglutinantes de nogo-a y uso farmaceutico de las mismasInfo
- Publication number
- AR072934A1 AR072934A1 ARP090103071A ARP090103071A AR072934A1 AR 072934 A1 AR072934 A1 AR 072934A1 AR P090103071 A ARP090103071 A AR P090103071A AR P090103071 A ARP090103071 A AR P090103071A AR 072934 A1 AR072934 A1 AR 072934A1
- Authority
- AR
- Argentina
- Prior art keywords
- binder molecule
- nogo
- same
- binding molecules
- polynucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una molécula aglutinante tal como por ejemplo anticuerpo que es capaz de aglutinarse con el polipéptido NogoA humano o NiG humano con una constante de disociacion < 1000nM, un polinucleotido que codifica dicha molécula aglutinante; un vector de expresion que comprende dicho polinucleotido; un sistema de expresion que comprende un polinucleotido capaz de producir una molécula aglutinante; una célula huésped aislada que comprende un sistema de expresion como se define anteriormente; el uso de dicha molécula aglutinante como un producto farmacéutico, especialmente en el tratamiento de una enfermedad del sistema nervioso periférico (SNP) y/o central (SNC); una composicion farmacéutica que comprende dicha molécula aglutinante; y un método de tratamiento de una enfermedad del sistema nervioso periférico (SNP) y/o central (SNC).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US174107P | 2007-11-02 | 2007-11-02 | |
| EP07119847 | 2007-11-02 | ||
| PCT/EP2008/064501 WO2009056509A1 (en) | 2007-11-02 | 2008-10-27 | Improved nogo-a binding molecules and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072934A1 true AR072934A1 (es) | 2010-09-29 |
Family
ID=39156235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103071A AR072934A1 (es) | 2007-11-02 | 2009-08-10 | Moleculas aglutinantes de nogo-a y uso farmaceutico de las mismas |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8163285B2 (es) |
| EP (1) | EP2207808B1 (es) |
| JP (1) | JP5698534B2 (es) |
| KR (1) | KR101574814B1 (es) |
| CN (1) | CN101910200B (es) |
| AR (1) | AR072934A1 (es) |
| AU (1) | AU2008317724B2 (es) |
| BR (1) | BRPI0818928B1 (es) |
| CA (1) | CA2704357C (es) |
| CL (1) | CL2008003240A1 (es) |
| CO (1) | CO6270357A2 (es) |
| CY (1) | CY1114345T1 (es) |
| DK (1) | DK2207808T3 (es) |
| ES (1) | ES2425768T3 (es) |
| HK (1) | HK1143597A1 (es) |
| HR (1) | HRP20130699T1 (es) |
| IL (2) | IL205357A (es) |
| JO (1) | JO2876B1 (es) |
| MA (1) | MA31805B1 (es) |
| MX (1) | MX2010004831A (es) |
| MY (1) | MY149546A (es) |
| NZ (1) | NZ584911A (es) |
| PE (1) | PE20090981A1 (es) |
| PL (1) | PL2207808T3 (es) |
| PT (1) | PT2207808E (es) |
| RU (1) | RU2513697C2 (es) |
| SI (1) | SI2207808T1 (es) |
| TN (1) | TN2010000199A1 (es) |
| TW (1) | TWI429656B (es) |
| WO (1) | WO2009056509A1 (es) |
| ZA (1) | ZA201002799B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012004773A1 (en) | 2010-07-09 | 2012-01-12 | Universite De Geneve | New uses of nogo-a inhibitors and related methods |
| EP2870177A1 (en) | 2012-07-05 | 2015-05-13 | Glaxo Group Limited | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
| HRP20220436T1 (hr) | 2015-11-03 | 2022-05-27 | Janssen Biotech, Inc. | Protutijela koja se specifično vežu na pd-1 i njihove uporabe |
| AU2020370751A1 (en) | 2019-10-24 | 2022-06-09 | Novago Therapeutics Ag | Novel anti-Nogo-A antibodies |
| WO2024041450A1 (zh) * | 2022-08-22 | 2024-02-29 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| AU642404B2 (en) | 1989-02-13 | 1993-10-21 | Schering Aktiengesellschaft Berlin Und Bergkamen | Novel thrombolytic |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| SK287323B6 (sk) * | 1998-11-06 | 2010-07-07 | University Of Z�Rich | Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie |
| CN1234730C (zh) * | 2001-12-30 | 2006-01-04 | 上海中科伍佰豪生物工程有限公司 | 鼠抗氯霉素单克隆抗体及其用途 |
| US7531178B2 (en) | 2002-06-07 | 2009-05-12 | Trigen Gmbh | Immunoadhesin comprising a glycoprotein VI domain |
| GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| ES2315664T3 (es) | 2003-06-30 | 2009-04-01 | Domantis Limited | Anticuerpos de dominio unico (dab) pegilados. |
| GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| PT1711530E (pt) * | 2003-12-22 | 2009-10-22 | Glaxo Group Ltd | Imunoglobulinas neutralizantes de nogo-a para o tratamento de doenças neurológicas |
| GB0329684D0 (en) * | 2003-12-22 | 2004-01-28 | Glaxo Group Ltd | Method |
| KR100918746B1 (ko) | 2004-09-06 | 2009-09-24 | 교와 핫꼬 기린 가부시키가이샤 | 항 ａ３３ 항체 |
| KR20080030960A (ko) * | 2005-07-05 | 2008-04-07 | 글락소 그룹 리미티드 | Ｎｏｇｏ―ａ에 특이적인 인간화된 항체 및 이의 약제학적용도 |
| GB0525662D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| BRPI0714334A2 (pt) | 2006-07-18 | 2013-05-14 | Centocor Inc | mimeticorpos de glp-1 humano aperfeiÇoados, composiÇÕes, mÉtodos e usos |
| AR069130A1 (es) | 2007-11-02 | 2009-12-30 | Novartis Ag | Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| KR101039751B1 (ko) | 2008-10-16 | 2011-06-09 | 한국생명공학연구원 | Ｔｍｐｒｓｓ４―특이적인 인간항체 |
-
2008
- 2008-10-27 NZ NZ584911A patent/NZ584911A/en not_active IP Right Cessation
- 2008-10-27 CA CA2704357A patent/CA2704357C/en not_active Expired - Fee Related
- 2008-10-27 CN CN2008801237017A patent/CN101910200B/zh not_active Expired - Fee Related
- 2008-10-27 MY MYPI2010001822A patent/MY149546A/en unknown
- 2008-10-27 BR BRPI0818928-5A patent/BRPI0818928B1/pt not_active IP Right Cessation
- 2008-10-27 EP EP08843849.4A patent/EP2207808B1/en active Active
- 2008-10-27 AU AU2008317724A patent/AU2008317724B2/en not_active Ceased
- 2008-10-27 JP JP2010531504A patent/JP5698534B2/ja active Active
- 2008-10-27 MX MX2010004831A patent/MX2010004831A/es active IP Right Grant
- 2008-10-27 WO PCT/EP2008/064501 patent/WO2009056509A1/en active Application Filing
- 2008-10-27 US US12/740,777 patent/US8163285B2/en active Active
- 2008-10-27 PL PL08843849T patent/PL2207808T3/pl unknown
- 2008-10-27 DK DK08843849.4T patent/DK2207808T3/da active
- 2008-10-27 RU RU2010122044/10A patent/RU2513697C2/ru active
- 2008-10-27 SI SI200831001T patent/SI2207808T1/sl unknown
- 2008-10-27 PT PT88438494T patent/PT2207808E/pt unknown
- 2008-10-27 KR KR1020107012080A patent/KR101574814B1/ko active IP Right Grant
- 2008-10-27 ES ES08843849T patent/ES2425768T3/es active Active
- 2008-10-30 PE PE2008001859A patent/PE20090981A1/es active IP Right Grant
- 2008-10-30 CL CL2008003240A patent/CL2008003240A1/es unknown
- 2008-10-30 JO JO2008490A patent/JO2876B1/en active
- 2008-10-31 TW TW097142276A patent/TWI429656B/zh not_active IP Right Cessation
-
2009
- 2009-08-10 AR ARP090103071A patent/AR072934A1/es unknown
-
2010
- 2010-04-21 ZA ZA2010/02799A patent/ZA201002799B/en unknown
- 2010-04-26 IL IL205357A patent/IL205357A/en active IP Right Grant
- 2010-04-30 MA MA32813A patent/MA31805B1/fr unknown
- 2010-04-30 CO CO10051504A patent/CO6270357A2/es active IP Right Grant
- 2010-04-30 TN TN2010000199A patent/TN2010000199A1/fr unknown
- 2010-10-18 HK HK10109838.5A patent/HK1143597A1/xx not_active IP Right Cessation
-
2012
- 2012-03-16 US US13/422,642 patent/US8758754B2/en active Active
- 2012-08-30 IL IL221723A patent/IL221723A/en active IP Right Grant
-
2013
- 2013-07-23 HR HRP20130699AT patent/HRP20130699T1/hr unknown
- 2013-08-08 CY CY20131100676T patent/CY1114345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063829A1 (es) | Moleculas de enlace de lingo y uso farmaceutico de las mismas | |
| PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
| EA201890315A1 (ru) | Молекулы антител, связывающие cd22 | |
| CL2008000670A1 (es) | Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras. | |
| WO2016100261A3 (en) | Method of treating cancer with cgamp or cgasmp | |
| PH12014502179A1 (en) | Ang2-binding molecules | |
| WO2015191911A3 (en) | Protein enriched microvesicles and methods of making and using the same | |
| MY176332A (en) | Multispecific antibody constructs | |
| MX353813B (es) | Moleculas de union a vegf. | |
| MA38308A1 (fr) | Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t | |
| ECSP066431A (es) | Moléculas de unión de nogo-a y uso farmacéutico de las mismas | |
| EA201791850A1 (ru) | Борсодержащие малые молекулы | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| MX2018011542A (es) | Moleculas biespecificas de celulas t activadas por proteasas. | |
| MX2014002668A (es) | Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas. | |
| TN2012000144A1 (en) | Dll4-binding molecules | |
| BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
| AR072934A1 (es) | Moleculas aglutinantes de nogo-a y uso farmaceutico de las mismas | |
| CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
| MX2018001686A (es) | Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco. | |
| MX2015009085A (es) | Peptido. | |
| SG10201806844SA (en) | Uv associated mtdna fusion transcripts and methods and uses thereof | |
| WO2015063452A3 (en) | Cell transport | |
| AR068038A1 (es) | Polipeptidos de la hormona de crecimiento modificada | |
| Huang et al. | Activation of OCT4 Enhances Ex Vivo Expansion of Phenotypically Defined and Functionally Engraftable Human Cord Blood Hematopoietic Stem and Progenitor Cells By Regulating HOXB4 Expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |